Over the last decade, classical chemotherapy has given way to new pharmacological approaches aimed at pathologically altered signal transduction pathways. Cannabis is one of the many ancient herbs used by American Indians for millennia. Nowadays, scientific data on its beneficial effects over a wide range of diseases are constantly increasing. There are many experimental data, as well as experimental models, and in humans studying the signal cascades influenced by the biologically active substances in it.
This review describes a number of studies and clinical trials that show the significant advances made in recent years in the use of cannabinoids to combat oncological diseases. In vivo and in vitro studies demonstrate the good tolerability and safety of cannabidiol in humans and animals. The positive effect of the substance in various conditions, inflammatory and oncological, should be taken into account, but more extensive research is needed to gain access to medical practice.
Vekov T., Lebanova H, Grigorov E. (2015). Pharmacotherapeutic recommendations for application of target oncological drug therapies for treatment of breast cancer in Bulgaria–therapeutic efficacy and cost effectiveness. Journal of BUON: official journal of the Balkan Union of Oncology, 20(6): 1420-1425.
Aggarwal S. K. (2016). Use of cannabinoids in cancer care: palliative care. Current Oncology, 23:33–S36.
Borgelt L.M., Franson K.L., Nussbaum A.M., Wang G.S. (2013). The pharmacologic and clinical effects of medical cannabis Pharmacotherapy, 33: 195–209.
Benz A.H., et al. (2013). Expression and functional relevance of cannabinoid receptor 1 in Hodgkin lymphoma. PloS one, 8(12): e81675
Campos A.C., Moreira F.A., Gomes F.V., Del Bel E.A., Guimarães F.S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci, 3364–78.
http://Dev-gwpharma.pantheonsite.io/about-us/news/gw-pharmaceuticals-announces-positive-phase-3-pivotal-study-results-epidiolex
Feng,= R., Milcarek,= C. A., Xie,= X.-Q. (2014). Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion. BMC Pharmacology & Toxicology; 15:30.
Gustafsson K., Wang X., Severa D., Eriksson M., Kimby E., Merup M., Christensson B., Flygare J., Sander B. (2008). Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation. International journal of cancer, 8:1025-1033.
Velasco G., Hernández-Tiedra S., Dávila D., Lorente M. (2016 )The use of cannabinoids as anticancer agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 4;64:259-66.
Massi P., Solinas M., Cinquina V.,Parolaro D. (2013). Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 27:303-312.
Machado Bergamaschi M., Helena Costa Queiroz R., Waldo Zuardi A., Crippa A. S. (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current drug safety, 4 :237-49.
Morelli M.B., et al. (2014). The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. International journal of cancer 11:2534-2546.
Murase R., Sumida T., Kawamura R., Onishi-Ishikawa A., Hamakawa H., McAllister S.D., Desprez, P.Y. (2016). Suppression of invasion and metastasis in aggressive salivary cancer cells through targeted inhibition of ID1 gene expression. Cancer letters, 377:11-16.
Murase R., et. al. (2014). Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. British journal of pharmacology, 171:4464-4477.
Pertwee A.C. Howlett M.E. Abood S.P. Alexander V., Di Marzo, M.R. et al. (2010). International Union of Basic and Clinical Pharmacology.Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev, 62.;588-631
Sachs, Jane, Erin McGlade, and Deborah Yurgelun-Todd. (2015). Safety and Toxicology of Cannabinoids. Neurotherapeutics, 12.4: 735-746.
Singer E., Judkins J., Salomonis N., Matlaf L., Soteropoulos P., McAllister S., Soroceanu L., (2015). Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell death & disease, 6:1601.
Velasco G., Hernández-Tiedra S., Dávila D., Lorente M. (2016) The use of cannabinoids as anticancer agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 4;64:259-66.
https://clinicaltrials.gov/ct2/show/NCT02255292
http://clinicaltrials.gov/show/NCT02392780
Email this article (Login required) 
